Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NKGen Biotech ( (NKGN) ) has provided an update.
NKGen Biotech has been chosen as the stalking horse bidder for NKMax in a court-managed rehabilitation process in South Korea, promising significant developments in NK cell therapies. This acquisition could secure global intellectual property rights for NKGen and facilitate the commercialization of troculeucel in markets where NK cell therapy is legal, such as Japan and South Korea. With up to $18 million in committed funding, the deal is anticipated to close in Q1 2025, potentially bolstering NKGen’s position in global cell therapy markets.
See more insights into NKGN stock on TipRanks’ Stock Analysis page.
